The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11111 malaria professionals are enjoying the free benefits of MalariaWorld today

artesunate–amodiaquine (ASAQ)

NOT Open Access | Consequences of restricting antimalarial drugs to rapid diagnostic test‐positive febrile children in south‐west Nigeria

November 18, 2019 - 16:12 -- NOT Open Access
Catherine Olufunke Falade, Adebola Emanuel Orimadegun, Daniel Chandramohan, et al.
Tropical Medicine International Health, Volume24, Issue 11 November 2019 : 1291-1300

To investigate the consequence of restricting antimalarial treatment to febrile children that test positive to a malaria rapid diagnostic test (MRDT) only in an area of intense malaria transmission.

Efficacy of artesunate–amodiaquine, dihydroartemisinin–piperaquine and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger

January 29, 2018 - 15:43 -- Open Access
Francesco Grandesso, Ousmane Guindo, Jean-François Etard, et al.
Malaria Journal 2018 17:52, 25 January 2018

All the three treatments evaluated largely meet WHO criteria (at least 95% efficacy). AS–AQ and AL–LM may continue to be used and DHA–PPQ may be also recommended as first-line treatment for uncomplicated falciparum malaria in Maradi.

Efficacy of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015

February 9, 2017 - 14:47 -- Open Access
Mateusz M. Plucinski, Pedro Rafael Dimbu, Filomeno Fortes, et al.
Malaria Journal 2017 16:62, 2 February 2017

No evidence was found to corroborate the specific allegation of artemisinin resistance in Lunda Sul.

Medical Condition: 
Subscribe to RSS - artesunate–amodiaquine (ASAQ)